Halozyme Therapeutics, Inc. (NASDAQ:HALO) is Pier Capital LLC’s 2nd Largest Position

Pier Capital LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 220,447 shares of the biopharmaceutical company’s stock after selling 2,185 shares during the quarter. Halozyme Therapeutics comprises about 1.7% of Pier Capital LLC’s holdings, making the stock its 2nd largest position. Pier Capital LLC’s holdings in Halozyme Therapeutics were worth $11,543,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in HALO. GAMMA Investing LLC raised its position in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 254 shares during the last quarter. Rise Advisors LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $33,000. Whittier Trust Co. purchased a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $27,000. Finally, Principal Securities Inc. acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total transaction of $617,500.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares in the company, valued at $10,384,868. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the sale, the director now directly owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total value of $617,500.00. Following the completion of the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $10,384,868. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,881 shares of company stock worth $3,084,984. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.0 %

Shares of HALO opened at $59.26 on Wednesday. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $65.53. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The firm has a 50 day simple moving average of $56.88 and a 200-day simple moving average of $47.97. The stock has a market cap of $7.51 billion, a price-to-earnings ratio of 24.49, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.68 earnings per share. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. The Goldman Sachs Group upped their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Benchmark reiterated a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. JPMorgan Chase & Co. reduced their price target on shares of Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, TD Cowen boosted their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.